Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Announces Quarterly Earnings Results

by · The Markets Daily

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02), Zacks reports. The company had revenue of $11.25 billion for the quarter, compared to analyst estimates of $11.21 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.34% and a negative net margin of 3.28%.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock traded up $0.53 on Thursday, hitting $15.75. The company’s stock had a trading volume of 606,724 shares, compared to its average volume of 1,055,133. Bayer Aktiengesellschaft has a fifty-two week low of $7.49 and a fifty-two week high of $15.76. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. The stock’s 50 day moving average is $13.45 and its 200-day moving average is $12.58. The company has a market capitalization of $61.88 billion, a PE ratio of -34.23, a PEG ratio of 2.01 and a beta of 0.57.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Check Out Our Latest Analysis on BAYRY

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.

Read More